176721-01-0

Basic information

• Product Name: α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol
• Synonyms: 1-(2,3-dimethylphenyl)-1-(1H-imidazol-4-triphenylmethyl)methanol;alpha-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol;α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol;(2,3-diMethylphenyl)(1-trityl-1H-iMidazol-4-yl)Methanol;1H-IMidazole-4-Methanol, α-(2,3-diMethylphenyl)-1-(triphenylMethyl)-;(2,3-Dimethylphenyl)(1-trityl-1H-imidazol-5-yl)methanol;(2,3-Dimethylphenyl)-(3-trityl-3H-imidazol-4-yl)methanol
• CAS NO: 176721-01-0
• Molecular Formula: C₃₁H₂₈N₂O
• Molecular Weight: 444.56682
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 176721-01-0.mol

Chemical Properties

• Boiling Point: 616.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Dichloromethane (Slightly), DMSO (Slightly, Heated), Ethy
• PKA: 13.08±0.20(Predicted)
• CAS DataBase Reference: α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol(176721-01-0)
• EPA Substance Registry System: α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol(176721-01-0)

Safety Data

• Hazardous Substances Data: 176721-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
α-(2,3-Dimethylphenyl)-1-(trityl)-1H-imidazole-4-methanol is used as an intermediate in the production of Medetomidine for its essential role in the synthesis process. Medetomidine is a potent and selective α2-adrenergic receptor agonist that is widely utilized in veterinary medicine for its sedative, analgesic, and anxiolytic effects. The compound's involvement in the production of Medetomidine highlights its importance in the pharmaceutical sector, contributing to the development of effective medications for animal healthcare.

Upstream product

• 576-23-8 2,3-dimethylbromobenzene 
• 33016-47-6 (1-tritylimidazol-4-yl)carboxaldehyde 
• 5779-93-1 2,3-dimethylbenzaldehyde 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 

Downstream Products

• 176721-02-1 4-<(2,3-dimethylphenyl)carbonyl>-1-(triphenylmethyl)imidazole 
• 86347-14-0 medetomidine 
• 113775-47-6 dexmedetomidine 
• 176721-03-2 4-<1-(2,3-dimethylphenyl)-1-hydroxyethyl>-1-(triphenylmethyl)imidazole 
• 1021949-47-2 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene 
• 86347-14-0 (+/-)-4(5)-<1-(2,3-Dimethylphenyl)ethyl-1H-imidazole> 
• 176721-04-3 (S)-dexmedetomidine-L-(+)-tartrate 

Relevant articles and documents

A right-US supporting [...] and its hydrochloride preparation method

Invention provides a right-US supporting [...] and its hydrochloride preparation method. In particular, the invention using carbon-carbon hydrogenation reduction catalyst and (R, S) - Duanphos composition as a catalyst to the double bond of a chiral catalytic reduction, directly by the enantiomeric excess percentage up to 99.9% of the right us holds the onamot to decide, the preparation method of the present invention short synthetic route, the product does not need to chiral separation, high yield.

Preparation method of dexmedetomidine hydrochloride and its intermediate

The invention discloses a preparation method of dexmedetomidine hydrochloride and its intermediate. A preparation method of dexmedetomidine L-tartrate comprises the steps of subjecting dexmedetomidineintermediate III and hydrogen to reduction reaction in an organic solvent in the presence of a chiral catalyst, and subjecting the reduced product and tartaric acid to neutralization reaction to obtain dexmedetomidine L-tartrate II, wherein the chiral catalyst is (+)-1,2-bis(2S-5S)-diethylphospholano-benzene(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate. The preparation method herein has ashort step path, has no need for chiral splitting, and has high total molar yield; the product prepared herein has high purity, reaches the standard for bulk pharmaceutical chemicals and is suitablefor industrial production.

A novel and facile route for the synthesis of medetomidine as the α2-adrenoceptor agonist

Abstract: We report here a novel and facile method for the synthesis of (±)-4(5)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (medetomidine) in a good yield in five steps. The method involves Wittig olefination of the phenylimidazolylketones, followed by a hydrogenation. We demonstrate that the Wittig alkenylation reaction provides a convenient step for the synthesis of medetomidine without requiring methylation and dehydration steps, which are problematic processes in the previous methods. Graphical Abstract: Novel route for the synthesis of medetomidine.[Figure not available: see fulltext.].

Method for preparing medetomidine and its salts

The invention provides an improved, highly efficient method for preparing Medetomidine, and its salts, in particular its pharmaceutically acceptable salts. The method utilizes the high reactivity of halogenated imidazoles towards transmetalation with Grignard reagents and the subsequent reaction with 2,3-dimethylbenzaldehyde.

Efficient synthesis of (S)-4(5)-[1-(2,3-dimethylphenyl) ethyl]imidazole tartrate, the potent α2 adrenoceptor agonist dexmedetomidine

(S,R)-4(5)-[1-(2,3-dimethylphenyl)ethyl]imidazole 5 is prepared in 41% yield, by a new reliable method from readily available starting materials. The separation of the enantiomers proceeds through the selective crystallisation of the (+)-tartrate of the (S) enantiomer 6 in the presence of the (R) enantiomer free base.